Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats

• Main Authors: Gudasheva TA, Povarnina P, Logvinov IO, Antipova TA, Seredenin SB
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-11-01
• Series: Drug Design, Development and Therapy
• Subjects: brain-derived neurotrophic factor; mimetic; PI3K/AKT; MAPK/ERK; ischemic stroke
• Online Access: https://www.dovepress.com/mimetics-of-brain-derived-neurotrophic-factor-loops-1-and-4-are-active-peer-reviewed-article-DDDT

Tatyana A Gudasheva,1 Polina Povarnina,1 Ilya O Logvinov,2 Tatyana A Antipova,2 Sergey B Seredenin3 1Department of Medicinal Chemistry, 2Department of Neuroprotective Pharmacology, 3Department of Pharmacogenetics, VV Zakusov Institute of Pharmacology, Moscow, Russia Background: Two dimeric dipeptides, bis-(N-monosuccinyl-L-seryl-L-lysine)hexamethy­lenediamide (GSB-106) and bis-(N-monosuccinyl-L-methionyl-L-serine) heptamethylenediamide (GSB-214), were designed based on the brain-derived neurotrophic factor (BDNF) loop 4 and loop 1 β-turn sequences, respectively. Earlier, both of these dipeptides were shown to exhibit neuroprotective activity in vitro (10-5–10-8 M). The present study aimed to investigate the mechanisms of action of these peptides and their neuroprotective activity in an experimental stroke model. Methods: We used western blot and HT-22 hippocampal neuronal cell line to investigate whether these peptides induced phosphorylation of the TrkB receptor and the AKT and ERK kinases. Rat middle cerebral artery occlusion (MCAO) was used as a stroke model. GSB-106 and GSB-214 were administered intraperitoneally (0.1 mg (1.3×10-7 mol)/kg) 4 hours after MCAO and daily for 7 days. The cerebral infarct volumes were measured with 2,3,5-triphenyltetrazolium chloride staining 21 days after MCAO. Results: Both compounds were shown to elevate the TrkB phosphorylation level while having different post-receptor signaling patterns. GSB-106 activated the PI3K/AKT and MAPK/ERK pathways simultaneously, whereas GSB-214 activated the PI3K/AKT only. In experimental stroke, the reduction of cerebral infarct volume by GSB-106 (~66%) was significantly greater than that of GSB-214 (~28% reduction), which could be explained by the fundamental role of the MAPK/ERK pathway in neurogenesis and neuroplasticity. Notably, between these two dipeptides, only GSB-106 exhibited antidepressant activity, as was found previously. Conclusion: The results provided support for the beneficial pharmacological properties of BDNF loop 4 mimetic GSB-106, thereby suggesting a potential role for this dipeptide as a therapeutic agent. Keywords: brain-derived neurotrophic factor, mimetic, PI3K/AKT, MAPK/ERK, ischemic stroke